96953 ⎘
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans; Cytokines; Lymphokines; Interferons; Chemokines Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS
#2CCR2 INHIBITORS AND METHODS OF USE
#3HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS
#4HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS
#5HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS
#6CYTOTOXIN-CCL8 PEPTIDE CONSTRUCTS AND USES THEREOF
#7TREATMENT OF INSECT BITE HYPERSENSITIVITY
#8PLURIPOTENT STEM CELL-DERIVED IMMUNE CELL INDUCING CHEMOTAXIS FOR HETEROGENEOUS IMMUNE CELLS
#9USE OF CCL26
#10HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS
#11CCL5 MRNA NANOPARTICLE AND METHODS OF USE THEREOF
#12ANTI-EGFRviii ANTIBODY, POLYPEPTIDE, CELL CAPABLE OF EXPRESSING SAID POLYPEPTIDE, PHARMACEUTICAL COMPOSITION COMPRISING SAID CELL, METHOD FOR PRODUCING SAID CELL, AND POLYNUCLEOTIDE OR VECTOR COMPRISING NUCLEOTIDE SEQUENCE ENCODING SAID POLYPEPTIDE
#13RNA CONSTRUCT
#14USE OF CCL13
#15DOSING REGIMENS FOR THE MOBILIZATION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS
#16CHIMERIC ANTIGEN RECEPTOR WITH ENDOGENOUS PROTEIN MOLECULE REPLACING SINGLE DOMAIN ANTIBODY
#17TAIL-CONJUGATED RNAS
#18ANTI-HER-2 ANTIBODY-CHEMOKINE FUSION PROTEIN, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
#19ENCAPSULATED RNA REPLICONS AND METHODS OF USE
#20NOVEL RECOMBINANT VACCINIA VIRUS AND USE THEREOF
#21CYCLIC CHEMERIN-9 DERIVATIVES
#22CHO CELL-DERIVED PROTEIN SECRETORY FACTORS AND EXPRESSION VECTORS COMPRISING THE SAME
#23NOVEL IMMUNOMODULATOR
#24ANAPLASTIC LYMPHOMA KINASE CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE
#25FUSOKINES INVOLVING CYTOKINES WITH STRONGLY REDUCED RECEPTOR BINDING AFFINITIES
#26Drug for Treating Cancer, Combination Drug, Drug Composition, Immune Responsive Cell, Nucleic Acid Delivery Vehicle, and Product
#27ARTIFICIAL IMMUNOSURVEILLANCE CHIMERIC ANTIGEN RECEPTOR (AI-CAR) AND CELLS EXPRESSING THE SAME
#28MUL TISPECIFIC PROCHEMOKINE THERAPEUTIC PROTEINS (PARK) AND METHOD OF MAKING AND USING THEREOF
#29FUSION PROTEINS COMPRISING A CYTOKINE AND SCAFFOLD PROTEIN
#30Tetanus toxoid and CCL3 improve DC vaccines
#31Methods and Compositions Relating to p62/SQSTM1 for the Treatment and Prevention of Inflammation-Associated Diseases
#32ONCOLYTIC ADENOVIRUS ENCODING A B7 PROTEIN
#33HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS
#34Methods for the treatment of tissue lesions with CCR2 agonists
#35Method of treating hypercytokinemia by administering the CCR5/CCL5 (RANTES) interaction inhibitor maraviroc
#36Method of treating COVID-19 by administering the CCR5/CCL5 (RANTES) interaction inhibitor maraviroc
#37Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions
#38PANTIDS FOR TREATMENT OF AUTOIMMUNE DISORDERS
#39PLASMA CELL CYTOKINE VEHICLE CONTAINING FUSION PROTEINS FOR TARGETED INTRODUCTION OF SIRNA INTO CELLS AND TISSUES
#40Methods and compositions relating to p62/SQSTM1 for the treatment and prevention of inflammation-associated diseases
#41Fusion protein comprising CCL3 variant and use thereof
#42Oncolytic adenovirus encoding a B7 protein or active fragment
#43Fusokines involving cytokines with strongly reduced receptor binding affinities
#44Glycosaminoglycan-antagonising fusion proteins
#45Modulation of CCR10 signals for treatment of skin and intestinal inflammatory diseases and infection
#46Plasma cell cytokine vehicle containing fusion proteins for targeted introduction of siRNA into cells and tissues
#47Tetanus toxoid and CCL3 improve DC vaccines
#48Future cardiac event biomarkers CCL3, CCL5, and CCL18
#49Cytokine
#50Fusokines involving cytokines with strongly reduced receptor binding affinities
#51Oncolytic adenovirus encoding a B7 protein
#52Oncolytic adenovirus encoding a B7 protein
#53Oncolytic adenovirus encoding a therapeutic protein or active fragment
#54Pegylated recombinant bacteriophage
#55Methods and compositions for modulating immune tolerance
#56Glycosaminoglycan-antagonising fusion proteins and methods of using same
#57Oncolytic adenovirus encoding a B7 protein or active fragment
#58Compositions and methods for delivering inhibitory oligonucleotides
#59Expression system for producing protein having a N-terminal pyroglutamate residue
#60Tetanus toxoid and CCL3 improve DC vaccines
#61Vaccines against HPV
#62Modulation of CCR10 signals for treatment of skin and intestinal inflammatory diseases and infection
#63Cytokine
#64VACCINES AGAINST HPV
#65COMPOSITIONS AND METHODS FOR TREATMENT OF EXERCISE-INDUCED PULMONARY HEMORRHAGE OR NASOPHARYNGEAL CICATRIX
#66Compositions and methods for delivering inhibitory oligonucleotides
#67Methods and compositions for modulating immune tolerance
#68MCPIP as wound therapy
#69Methods of treating pancreatitis
#70Method of treating eosinophilia by administering an immunomodulating peptide
#71Control agent for controlling undifferentiated state and use thereof
#72METHODS OF TREATING INFLAMMATION
#73Method for inducing in vivo migration of stem cell
#74Cytokine derivatives
#75Heterodimeric human IgG1 polypeptides with isoelectric point modifications
#76GLYCOSAMINOGLYCAN-ANTAGONISING MCP-1 MUTANTS AND METHODS OF USING SAME
#77VACCINES, IMMUNOTHERAPEUTICS AND METHODS FOR USING THE SAME
#78Nucleic acid molecules encoding rantes, and compositions comprising and methods of using the same
#79Peptides for active anti-cytokine immunization
#80Viral chemokine-antigen fusion proteins
#81Method for producing proteins in that lack detectable cross binding activity to antibodies against host cell antigens
#82VACCINES, IMMUNOTHERAPEUTICS AND METHODS FOR USING THE SAME
#83Peptides for active anti-cytokine immunization
#84Molecular Antigen Array
#85CCL17
#86Antagonists against interaction of PF4 and RANTES
#87Chemokine-Chaperone Fusion Proteins
#88GLYCOSAMINOGLYCAN-ANTAGONISING MCP-I MUTANTS AND METHODS OF USING SAME
#89Molecular Antigen Array
#90Method for treating atherosclerosis by administering human MCP1 fusions
#91Peptides for active anti-cytokine immunization
#92Compositions and methods for delivering inhibitory oligonucleotides
#93GAG BINDING PROTEIN
#94Viral chemokine-antigen fusion proteins
#95Cytokine
#96Angiotensin peptide-carrier conjugates and uses thereof
#97Methods and compositions for modulating immune tolerance
#98Future cardiac event biomarkers CCL3, CCL5 and CCL18
#99CHEMOKINE ANALOGS
#100MCPIP Protection Against Cardiac Dysfunction
#101GAG BINDING PROTEINS
#102Glycosaminoglycan-antagonising MCP-1 mutants
#103Methods for treating rheumatoid arthritis and multiple sclerosis using MCP1 fusions
#104MCP-1 SPLICE VARIANTS AND METHODS OF USING SAME
#105Peptides for active anti-cytokine immunization
#106METHODS OF TREATING INFLAMMATION
#107Nucleic acids encoding CCL27
#108Isolated MCPIP and Methods of Use
#109Method for detecting IL-16 activity and modulation of IL-16 activity based on rantes proxy protein levels
#110Cytokine derivatives
#111Engineered fusion molecules immunotherapy in cancer and inflammatory diseases
#112MAMMALIAN CHEMOKINE REAGENTS
#113HUMAN SIGNAL PEPTIDE-CONTAINING PROTEINS
#114Antigen Arrays for Treatment of Allergic Eosinophilic Diseases
#115Chimeric polypeptides containing chemokine domains
#116ANTIFIBROTIC THERAPY
#117Method of diagnosis of inflammatory disease using eotaxin antibodies
#118Processed human chemokines PHC-1 and PHC-2
#119HUMAN IL-17F AND OTHER IL-17F-RELATED PROTEINS AND METHODS RELATED THERETO
#120Methods for construction and screening of libraries of chemokine variants
#121Leukocyte Adhesion Inhibitor-1 (LAI-1)
#122GAG binding protein
#123Chemokine Ccl18 as a Biomarker
#124Chemokine Antagonists
#125Chemokine panec-1 antibodies
#126Antagonists against interaction of PF4 and RANTES
#127Molecular antigen arrary
#128Myeloid progenitor inhibitory factor-1 (MPIF-1) polypeptides
#129Peptides for active anti-cytokine immunization
#130Human circulating cytokine CC-1
#131Antibodies to chemokine β-15
#132GAG binding proteins
#133Antibodies to human eotaxin
#134MAMMALIAN CHEMOKINE REAGENTS
#135Therapeutic uses of chemokine variants
#136Human derived monocyte attracting purified protein product useful in a method of treating infection and neoplasms in a human body, and the cloning of full length cDNA thereof
#137Human Chemokine HCC-1 Polypeptides To Improve Stem Cell Transplantation
#138Human Chemokines CKBeta-4 and CKBeta-10/MCP-4
#139Antiviral compositions which inhibit paramyxovirus infection
#140Chimeric polypeptides containing chemokine domains
#141Isolated MCPIP and methods of use
#142Antigen arrays for treatment of bone disease
#143Antigen arrays for treatment of allergic eosinophilic diseases
#144MCP-1 splice variants and methods of using same
#145Angiotensin peptide-carrier conjugates and uses thereof
#146Chemokine PANEC-2 polypeptides and compositions and methods related thereto
#147Chemokine analogs for the treatment of human diseases
#148Molecular antigen array
#149Chemokine Beta-15
#150MCP1 fusions
#151Antagonists of MCP proteins
#152Human signal peptide-containing proteins
#153Anti-CCL27 antibodies
#154Compositions and uses of secreted polypeptide, Zsig98
#155Human signal peptide-containing proteins
#156Peptides for active anti-cytokine immunization
#157Antibodies to myeloid progenitor inhibitory factor-1 (MPIF-1)
#158Eotaxin: eosinophil chemotactic cytokine
#159Rantes-derived peptides with anti-hiv activity
#160Mammalian chemokine reagents
#161Human chemotactic cytokine
#162Chemokine beta-7 variants
#163Preparation and use of superior vaccines
#164Angiotensin peptide-carrier conjugates and uses thereof
#165Mono-and dual chemokine/cytokine constructs
#166Compounds and methods to inhibit or augment an inflammatory response
#167Macrophage derived chemokine (MDC), MDC analogs, MDC inhibitor substances and uses thereof
#168Human chemokine β-9 viral vectors
#169Polynucleotides encoding leukocyte adhesion inhibitor-1 (LAI-1)
#170Compositions useful as ligands for the formyl peptide receptor like 1 receptor and methods of use thereof
#171Therapeutic targeting of PARC/CCL18 and its signaling in pulmonary fibrosis
#172Treatment methods for eotaxin mediated inflammatory conditons
#173Antibodies to human chemokine beta-9
#174Therapeutic uses for MDC and MDC antagonists
#175Suppression of post-transplant arteriosclerosis
#176Inhibitors of binding between proteins and macromolecular ligands
#177Amino-terminally truncated rantes as chemokine antagonists
#178Chemokine mutants acting as chemokine antagonists
#179Antibodies to human IL-17F and other CTLA-8-related proteins and methods related thereto
#180N-terminal modification of RANTES and methods of use
#181Amino-terminally truncated MCP-2 as chemokine antagonists
#182Antibody and chemokine constructs and their use in the treatment of infections of immunological diseases
#183Eotaxin : eosinophil chemotactic cytokine
#184Use of amino-terminally truncated RANTES to inhibit HIV viral replication
#185Method for the production of an N-terminally modified chemotactic factor
#186Human chemotactic protein
#187Human circulating cytokine CC-1
#188Methods for using chemokine teck
#189Chemokines with amino-terminal modifications
#190Detection and treatment of breast disease